Having another partner for open territories de risk this company so much.
It will be two (or even more) Pharma companies who have done a deep analysis of the data and decided to invest.
In my view the risk reward ratio goes up 70%....With potential upto 1bn in milestones plus 15-20% royalties....anything less than 1bn Mc is a good buying opportunity post March results...
Just a word of caution, no one knows the outcome so there is always a chance the trial doesn't meet expectations despite all best efforts so that's why 70% risk ration is key ...
Having another partner for open territories de risk this company...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $209.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 91570 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 7922 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |